# IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT

> **NCT03696537** · PHASE1 · TERMINATED · sponsor: **Naoyuki G. Saito, M.D., Ph.D.** · enrollment: 6 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Fludarabine
- **RADIATION:** Total Marrow Irradiation (TMI)

## Key facts

- **NCT ID:** NCT03696537
- **Lead sponsor:** Naoyuki G. Saito, M.D., Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-29
- **Primary completion:** 2020-07-08
- **Final completion:** 2021-04-13
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Extreme toxicity
- **Last updated:** 2022-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03696537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03696537, "IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03696537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*